It is known that radiotherapy and chemotherapy are very destructive, toxic and act nonspecifically to all fast-growing cells, including blood cells, the immune cells of the gut and useful microorganisms. Side effects of chemotherapy and radiation therapy are sometimes so strong that many patients have to refuse further treatment because of severe intoxication, serious malfunctions of gastrointestinal tract and liver. Traditionally, the problem is solved by diet. In case of serious health deterioration of a patient, treatment is postponed until the normalization of condition. The company has developed technology of production of bio-product containing a high concentration of live active bifidus bacteria and lacto-propionic acid bacteria (probiotics), for the treatment of patients after chemotherapy or radiation therapy. Bioproduct is a skimmed milk drink with a pleasant taste. Skimmed milk bioproducts based on liquid probiotics helps to cleanse the body of endotoxins generated during aggressive cancer therapy, ensure recovery of bowel and liver, and normalize immune responses. Thereby the side effects of chemotherapy and radiation therapy are smoothed, the patients feel better, full antitumor treatment continues without interruption. Long-term observations of the application of liquid probiotic in the rehabilitation of patients undergoing chemo or radiation therapy, clearly demonstrate that the drug intake during and between courses of chemotherapy or radiation therapy significantly improves the psychosomatic condition of patients. The effectiveness of the company's products has been proven by numerous clinical trials in leading clinics of Russia. Similar specialized drugs reducing the side effects of cancer treatment and quality of life of cancer patients are not currently presented on the market. The company is interested in finding partners for the clinical testing of liquid probiotics in cancer patients, developing guidelines for the use of the drug in radiation and chemotherapy. The company is ready to begin the development of a modified more effective drug, designed specifically for the rehabilitation of patients with cancer.